Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST by M. Urbini et al.
R E S E A R CH A R T I C L E
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P
WT GIST
Milena Urbini1 | Valentina Indio1 | Giuseppe Tarantino1 | Gloria Ravegnini2 |
Sabrina Angelini2 | Margherita Nannini3 | Maristella Saponara3 | Donatella Santini4 |
Claudio Ceccarelli4 | Michelangelo Fiorentino5 | Bruno Vincenzi6 | Elena Fumagalli7 |
Paolo Giovanni Casali7 | Giovanni Grignani8 | Andrea Pession9 | Andrea Ardizzoni10 |
Annalisa Astolfi1 | Maria Abbondanza Pantaleo3
1"Giorgio Prodi" Cancer Research Center,
University of Bologna, Bologna, Italy
2Department of Pharmacy and Biotechnology,
FaBit; University of Bologna, Bologna, Italy
3Department of Specialized, Experimental and
Diagnostic Medicine, S.Orsola-Malpighi
Hospital, University of Bologna, Bologna, Italy
4Pathology Unit, S.Orsola-Malpighi Hospital,
University of Bologna, Bologna, Italy
5Laboratory of Oncological and Transplant
Molecular Pathology—Pathology Unit,
S.Orsola-Malpighi Hospital, University of
Bologna, Bologna, Italy
6Department of Medical Oncology, University
Campus Bio-Medico, Rome, Italy
7Medical Oncology Unit 2, Medical Oncology
Department, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy
8Sarcoma Unit, Candiolo Cancer Institute -
FPO, IRCCS, Candiolo, Italy
9Department of Medical and Surgical Sciences,
S.Orsola-Malpighi Hospital, University of
Bologna, Bologna, Italy
10Division of Medical Oncology, S.Orsola-
Malpighi Hospital, Bologna, Italy
Correspondence
Annalisa Astolfi, “Giorgio Prodi” Cancer
Research Center, University of Bologna,
S.Orsola-Malpighi Hospital, Via Massarenti
11, Bologna 40138, Italy.
Email: annalisa.astolfi@unibo.it
Funding information
Petra Srl; Fondazione Isabella Seràgnoli
Abstract
Gastrointestinal stromal tumors (GIST) lacking mutations in KIT/PDGFRA or RAS
pathways and retaining an intact SDH complex are usually referred to as
KIT/PDGFRA/SDH/RAS-P WT GIST or more simply quadruple WT GIST (~5% of all
GIST). Despite efforts made, no recurrent genetic event in quadruple WT GIST has
been identified so far. To further investigate this disease, we performed high throughput
copy number analysis on quadrupleWT GIST specimens identifying a recurrent focal gain
in band 11q13.3 (involving FGF3/FGF4) in 6/8 cases. This event was not found in the
other molecular GIST subgroups. FGF3/FGF4 duplication was associated with high
expression of FGF4, both at mRNA and protein level, a growth factor normally not
expressed in adult tissues or in KIT/PDGFRA-mutated GIST. FGFR1 was found to be the
predominant FGF receptor expressed and phosphorylation of AKT was detected,
suggesting that a FGF4-FGFR1 autocrine loop could stimulate downstream signaling in
quadruple WT GIST. Together with the recent reports of quadruple WT cases carrying
FGFR1 activating alterations, these findings strengthen the hypothesis of a potential
involvement of FGFR pathway deregulation in quadrupleWT GIST, which may represent
a rationale for novel therapeutic approaches.
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1 | INTRODUCTION
Gastrointestinal stromal tumors (GIST) not harboring mutations in
KIT or platelet-derived growth factor receptor alpha (PDGFRA)
receptors (~10%-15% of adult cases) are often referred to as
KIT/PDGFRA wild-type (WT) GIST.1 Between 20% and 40% of
KIT/PDGFRA WT GIST show loss of function of the succinate dehy-
drogenase complex (SDH), designated as SDH-deficient GIST, recog-
nized by the loss of subunit B (SDHB) protein expression.2–4
Moreover, another subgroup (~15% of KIT/PDGFRA WT GIST) har-
bours mutations in BRAF/RAS or NF1 and are referred to as RAS-
pathway (RAS-P) mutant GIST.5–7 The remaining cases, lacking
mutations in the KIT/PDGFRA or RAS pathways, and retaining an
intact SDH complex, are usually referred to as KIT/PDGFRA/SDH/
RAS-P WT GIST or more simply quadruple WT GIST, accounting
approximately for 50% of KIT/PDGFRA WT GIST and 5% of all
GIST.8 These cases show a transcriptome profile that profoundly dif-
fers from KIT/PDGFRA- and SDHA-, or possibly all SDH-mutant
GIST, indicating that quadruple WT GIST could represent another
unique group within the family of GIST.9,10
Recently, despite the homogenous transcriptome profile, the
extensive molecular characterization of quadruple WT GIST failed to
detect any recurrent genetic event underlying the disease, conversely
providing evidence of a great molecular heterogeneity, with many dif-
ferent and sometimes private mutational events such as fusion genes
involving ETV6-NTRK3 or FGFR1 and mutations on FGFR1, TP53,
MAX, and MEN1.10–13 However, whether these alterations were driver
or secondary events is still to be proven, even if the heterogeneity of
the mutated genes and the lack of any recurrent genetic feature sup-
ports the view that the underlying shared pathway of quadruple WT
GIST is still to be uncovered. In this study, a deep molecular analysis
was performed to further investigate the biological background of
this very rare subgroup of disease that extensively differs from
other GIST.
2 | MATERIALS AND METHODS
2.1 | Patients and tumor samples
Tissue samples of eight quadruple WT, five fresh frozen (FF), and
three formalin-fixed paraffin-embedded (FFPE), being negative for
mutations in KIT, PDGFRA, SDHx, and RAS-P genes, were central-
ized at “Giorgio Prodi” Cancer Research Center (CIRC), University
of Bologna, within a multicentric collaborative project. Patients and
tumor characteristics are listed in Table 1. GIST diagnosis was based
on histologic evaluation and on immunohistochemistry of CD117
and DOG1 and was centrally reviewed. In addition to Sanger
sequencing performed at the time of diagnosis, the mutational sta-
tus of KIT, PDGFRA, BRAF, KRAS, SDHx, and NF1 was evaluated
through a custom amplicon sequencing panel using Truseq Custom
Amplicon low input kit (Illumina). Moreover, SDH deficiency was
excluded by IHC of SDHB. Seven out of these eight quadruple WT
cases were also analyzed through whole exome sequencing in a
previously published article10 and relevant alterations were
reported in four cases: a truncating mutation of CTNND2 in
GIST127, a homozygous frameshift deletion of MEN1 and TP53
mutation in GIST320, a frameshift deletion on MAX combined with
a germline variant on NF1 (p.R2573L) in GIST268, an activating
mutation (p.N546K) of FGFR1 in GIST409 (Table 1).
This study was approved by the local institutional ethical commit-
tee of Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi
(number 113/2008/U/Tess).
2.2 | Copy number
Whole chromosome gains and losses and copy number aberrations
(deletions and duplications) were determined in quadruple WT cases
using CytoScan HD or Oncoscan CNV Plus array (Thermo Fisher Sci-
entific, Milan, IT) for FF or FFPE specimens, respectively. Copy num-
ber data were analyzed and visualized with Chas 3.1 (Thermo Fisher
Scientific).
TABLE 1 Patients and tumor characteristics
Patient
id Sex Age Site
Size
(cm)
Mitotic
count
Risk
classification
Lymph
node
metastasis
Distant
metastasis
Relevant
mutationsa
Tissue
Type
FGF4
gain
FGF4
expression
GIST127 F 63 Ileum 5-10 6-10 High No Yes CTNND2 p.S996fs FF Positive High
GIST133 M 57 Duodenum 1.6 <5 Very low No No None FF Positive High
GIST400 M 69 Duodenum NA NA NA No No None FF Positive High
GIST401 F 45 Duodenum NA NA NA No No None FF Positive High
GIST409 M 45 Ileum NA NA NA No No FGFR1 p.N546K FF Negative Negative
GIST320 M 73 Ileum 13 <5 High No No MEN1 p.L83fs
TP53 p.V216M
FFPE Positive High
GIST219 M 44 Duodenum 6.5 >5 High No Yes Unknown FFPE Positive High
GIST268 M 50 Ileum 8.5 2 Intermediate No No NF1 p.R2573L
MAX p.K34fs
FFPE Negative Negative
aExome sequencing performed by Pantaleo et al.10
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As reference control dataset we used copy number data available
online from other GIST samples: GSE93077 from Schaefer et al14 and
GSE20709 from Astolfi et al15 GSE93077 is a series of 9 KIT mutated
cases for which copy number data produced using CytoScan HD Array
was available. GSE20709 is a series of 21 KIT/PDGFRA and 4 SDHx
mutated GIST analyzed with SNP6.0 array. Moreover, SNP6.0 array data
of additional 10 KIT/PDGFRA mutated GIST were used. Global copy
number alteration were analyzed with Chas 3.1 and FGF3/FGF4 locus
was manually checked for putative focal alterations.
2.3 | Copy number Taqman assays
Validation of FGF4 copy number state was performed on FF quadruple
WT tumor samples, using FAM-labeled TaqMan Copy Number Assays
(Thermo Fisher Scientific) targeting FGF4 (Hs02374436_cn) and
XXRA1 (Hs03782780_cn), respectively, located in chromosome bands
11q13.3 and 11q13.4, were used on ABI Prism 7900HT platform
(Applied Biosystems, Foster City, California). TaqMan RNaseP Control
Reagent (VIC-labeled; Thermo Fisher Scientific) was used as internal
reference control. Estimation of FGF4 copy number was done using
DDCt method in comparison with XRRA1 and with a normal diploid
sample (calibrator). All experiments were performed in triplicate on
the 5 quadrupleWT cases vs 10 KIT/PDGFRA mutant GIST.
2.4 | RNA-sequencing (RNA-seq)
RNA-seq data was analyzed on the 8 quadruple WT GIST, 5 SDH defi-
cient GIST and 16 KIT/PDGFRA mutant samples. FF samples were
analyzed as described in the previous publication.10 For FFPE samples,
RNA was extracted using RecoverAll Total Nucleic Acid Isolation
Kit (Thermo Fisher Scientific) and cDNA libraries were synthesized from
100 ng total RNA with TruSeq RNA Exome (Illumina) according to
the manufacturer's recommendations. Then, libraries were pooled and
hybridized to probes specific for the enrichment of coding regions.
Libraries were quality-checked and sized with Bioanalyzer 2100 (Agilent
Technologies), and then quantified using a fluorimetric assay (QuantIT
Picogreen assay, Thermo Fisher Scientific). Paired-end libraries were
amplified and ligated to the flowcell by bridge PCR, and sequenced at
2 × 80 bp on NextSeq500 instrument (Illumina), producing an average of
50 × 106 reads per sample. After FASTQ generation and trimming of low
quality bases and sequencing adapters, gene expression was quantified
using the tool Kallisto (https://pachterlab.github.io/kallisto/) adopting the
Transcript per Million (TPM) normalization.
2.5 | qRT-PCR
FGF4 qRT-PCR was performed on cDNA synthesized from FF tumor
samples (5 quadruple WT, 5 SDH deficient, and 18 KIT/PDGFRA mutant
GIST). cDNA was obtained with First Strand cDNA synthesis kit (Roche)
and FGF4 expression level was evaluated in using quantitative-PCR on
Light Cycler 480 instrument (Roche). Fold change was evaluated using
DDCt method, using GAPDH as housekeeping gene. Primer used were:
FGF4_Fw 50- CCAGCCGGTTCTTCGTG-30; FGF4_Rev 50- ATCGGTGAA
GAAGGGCGAG-30; GAPDH_Fw 50-CGGGAAGCTTGTCATCAAT-30 and
GAPDH_Rev 50- GACTCCACGACGTACTCAGC-30.
2.6 | Western blot
Frozen tumor samples were homogenized in RIPA buffer containing
phosphatase and protease inhibitors (Halt Protease and Phosphatase
Inhibitor Cocktail, Thermo Fisher Scientific) and immunoblotted. The
following primary antibodies were used: FGFR1 (#9740, Cell Signaling,
Leiden, the Netherlands), FGFR2 (#11835, Cell Signaling), FGF4
(PA5-52804, Thermo Fisher Scientific), phospho-AKT (#9271, Cell
Signaling), Phospho-c-KIT (#3391, Cell Signaling) and β-Actin (A1978,
Sigma-Aldrich, Milan, Italy).
3 | RESULTS
3.1 | FGF3/FGF4 locus is recurrently duplicated in
quadruple WT GIST
High throughput copy number analysis was performed in eight quadruple
WT GIST, highlighting the presence of a recurrent focal gain of one copy
in chromosome 11q13.3 cytoband in six samples. The cryptic copy num-
ber gain detected overlapped the FGF3/FGF4 locus, and was present
either in tumors with a normal disomic chromosome 11 (Sample
GIST400, 401, 133, and 219) and in two other cases (GIST127 and 320),
that showed complete loss of the q-arm of chromosome 11 (Figure 1A).
In addition GIST127 showed a complex copy number state in the region
spanning 11q with the presence of the intrachromosomal rearrangements
MARK2-PPFIA1 and PLA2G16-ATL3, involving genes located in close
proximity of the 11q13.3 copy number gain (Figure 1B). Conversely, the
two cases without 11q13.3 focal gain were known to carry putative path-
ogenetic alterations (Table 1), since GIST268 harboured a germline rare
variant on NF1 and a somatic frameshift deletion on MAX and GIST409
carried an activating mutation (p.N546K) of FGFR1.10
Quantitative PCR on the FGF4 region was employed to validate
the copy number gain in FF quadruple WT, confirming the presence of
the focal duplication of FGF4 in the four previously identified cases
(GIST127, GIST133, GIST400, GIST401) while, as expected, GIST409
did not show the FGF4 copy number gain (Figure 1C).
These findings reveal the presence of a recurrent duplication of
the 11q13.3 region, encompassing FGF3/FGF4, in one of the two
alleles at chr11 in quadruple WT GIST. To further assess whether
11q13.3 gain was present also in other GIST molecular subgroups, we
analyzed previously produced data of 44 KIT/PDGFRA/SDHx mutant
GIST (9 CytoScan HD14 and 35 SNP6.015 arrays). Among these, four
cases showed alterations involving 11q (two cases with trisomy of
chromosome 11 and two cases with loss of the entire q-arm), how-
ever no focal alteration involving the FGF3/FGF4 locus was detected.
GIST133, a quadruple WT GIST, was found positive for FGF3/FGF4
gain using both CytoScan HD and SNP6.0 arrays, confirming the sen-
sibility of both array types to detect the cryptic gain (data not shown).
URBINI ET AL. 3
3.2 | FGF4 is highly expressed in quadruple WT GIST
carrying FGF3/FGF4 duplication
To understand the pathogenic effect of FGF3/FGF4 focal copy number
gain, we analyzed the expression profile of 8 quadrupleWT GIST in com-
parison with 5 SDH deficient and 16 KIT/PDGFRA mutant GIST. While
FGF3 was generally lowly expressed and not significantly altered among
GIST subgroups, FGF4 was found highly expressed only in quadrupleWT
samples carrying FGF4 gain (qWT 11q13.3+), with an average expression
of 163 TPM. Interestingly, the two quadruple WT cases not expressing
FGF4 were those without 11q13.3 gain (GIST268 and GIST409),
supporting the correlation between the gain and the overexpression of
FGF4 (Figure 2A). Conversely, FGF4 was almost not expressed in
KIT/PDGFRA mutant cases (average TPM = 0.96; P-value = .0005) and
significantly lowly expressed in SDH mutant cases (average TPM = 19;
P-value = .0043) with respect to qWT11q13.3+ (Figure 2A). Through
qRT-PCR, FGF4 was confirmed as poorly expressed in an additional
cohort of 23 KIT/PDGFRA/SDH mutant GIST in comparison with qWT
11q13.3+, further supporting that the overexpression of FGF4 is exclu-
sive for quadrupleWT cases with the focal duplication of the growth fac-
tor (Figure 2B).
Expression of FGF4 receptors was evaluated at the mRNA level,
finding two out of four FGF receptors (FGFR1 and 2) expressed in all
GIST subgroups, with FGFR1 being the most expressed (FGFR1
average-TPM = 361 vs FGFR2 average-TPM = 47) (Figure 2A). At the
protein level FGFR1 was confirmed as the predominant FGF receptor
commonly expressed in all GIST, while the ligand FGF4 was detected
only in the quadruple WT subgroup (Figure 2C). GIST409, similarly to
KIT-mutant GIST, did not express FGF4 protein (Figure 2C).
We then investigated whether FGF4 could activate its down-
stream signaling. Interestingly, while KIT phosphorylation was not
detected in quadruple WT GIST, phosphorylation of AKT was
detected also in quadruple WT GIST, suggesting the presence of a
FGF4/FGFR1 autocrine loop that activates downstream signaling in
this subgroup (Figure 2D).
F IGURE 1 Identification of a recurrent focal gain of FGF3/FGF4 locus in quadruple WT GIST. A, Focal gain of chr11q13.3 identified in
six cases (four FF light cyan background, two FFPE light yellow background) of quadruple WT GIST through high resolution copy number
arrays. At the bottom of the image is showed the position of FGF4 in the chr11 long arm while at the top a magnification on the FGF4
region, blue boxes indicate region of copy number gain. B, Circo plot of GIST127 chromosome 11 long arm in which are showed the
experimentally-validated rearrangements involving MARK2-PPFIA1 (in purple) and PLA2G16-ATL3 (green) that support the complexity of
copy number alterations. C, Validation of FGF4 copy number gain through qPCR using Taqman assays. Four FF quadruple WT GIST (in light
cyan) carried the gain of FGF4 (with an estimated copy number = 3), while one quadruple WT and 10 KIT/PDGFRA mutant cases were
normal diploid (CN = 2; P-value <.01). FGF4 relative copy number was evaluated in comparison with one normal diploid sample (calibrator)
and XRRA1 (located on the adjacent cytoband of FGF4, chr11q13.4). P-value was calculated with Mann-Whitney test [Color figure can be
viewed at wileyonlinelibrary.com]
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Together these findings suggest that the recurrent 11q13.3 dupli-
cation detected in quadruple WT is the pathogenic driver event, pro-
voking the overexpression of FGF4 and the activation of FGFR1
downstream signaling.
4 | DISCUSSION
In the present study we discovered the presence of a recurrent focal
copy number gain encompassing the FGF3/FGF4 locus specifically in
quadruple WT GIST, which was associated with a high expression of
FGF4. Fibroblast growth factor 4 has a key role in maintaining the
self-renewal potential of normal stem cells16 and it is usually not
expressed in human adult tissues (with the exception of testis).17 It
was firstly identified as an oncogene in gastric cancer and Kaposi's sar-
coma18,19 and it has been found overexpressed in several malignancies
(including germ cell tumors, ovarian cancer, hepatocellular carcinoma,
and lung adenocarcinoma), generally associated with aggressiveness and
poorer prognosis.17,20–22 In our cases, the cryptic duplication of FGF3/
FGF4 was predominantly found in tumors with a normal disomic chro-
mosome 11, however, it was detected also in cases showing the com-
plete loss of one of the two copies of the q-arm of the chromosome.
Both genes are located in the 11q13 cytoband, and together with
FGF19, EMS1, and CCND1 are frequently amplified in solid cancers
including breast cancer, squamous cell carcinoma, esophageal cancer,
bladder cancer, and hepatocellular carcinoma.23–27 Interestingly, through
in vitro and in vivo studies in hepatocellular carcinoma, FGF3/FGF4 focal
amplification was demonstrated to be related to FGF3 and FGF4 over-
expression and to an increased sensitivity to sorafenib.21
Noticeably, while FGF4 was absent or slightly expressed in
KIT/PDGFRA/SDH-mutated GIST, it was found highly expressed in qua-
drupleWT GIST, supporting a causal role of the gain in the transcriptional
activation of the gene. On the other hand, no significant upregulation of
FGF3 was detected, indicating that this gene may not be the biologically-
relevant pathogenic event. The mechanism for which the duplication
F IGURE 2 Expression of FGF4 and FGF receptors in quadrupleWT with respect to KIT/PDGFRA/SDH mutant GIST. A, Log10 TPM counting,
calculated from RNA-sequencing data of 8 quadrupleWT in comparison with 5 SDH deficient and 16 KIT/PDGFRA mutant GIST. FGF4 (left panel)
was significantly overexpressed in quadrupleWT GIST carrying 11q13.3 gain. P-value was calculated with Mann-Whitney test (**<.01; ***<.001).
On the right panel, FGF receptors mRNA expression level is shown: while FGFR3 and FGFR4 are lowly expressed, FGFR1 and FGFR2 are highly
expressed and present in quadrupleWT GIST at a levels comparable to KIT/PDGFRA/SDH mutant cases. B, FGF4 mRNA relative expression
evaluated through qRT-PCR on FF tumor samples (5 quadrupleWT, 5 SDH deficient, and 18 KIT/PDGFRA mutant GIST). C, Western blot
evaluation of protein expression level of FGF4, FGFR1 and FGFR2 in quadrupleWT GIST. Cell lines lysates were used as positive controls:
untreated GIST48 and GIST48 supplemented with 100 μg/mL of recombinant FGF4 protein (for FGFR1 and FGF4 expression) and untreated
SNU-16 (for FGFR2 expression). β-Actin was used as loading control. D, Evaluation of KIT and AKT phosphorylation level in GIST tumors. β-Actin
was used as loading control [Color figure can be viewed at wileyonlinelibrary.com]
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found in quadrupleWT GIST leads to the re-activation of FGF4 transcrip-
tion is not clear. However, it could be hypothesized that this alteration
may cause conformational or epigenetic changes able to disrupt the
silencing of the gene, possibly through an escape from the epigenetic
repression of FGF4 transcription.28
The novelty and interest of these findings are that, for the first
time, a recurrent event shared by the majority of quadruple WT GIST
was identified in this subgroup of disease that until now was charac-
terized only by private and heterogeneous molecular events. There-
fore, this opens a new molecular path of study in this very rare
disease. Predominantly, quadruple WT GIST positive for FGF4 duplica-
tion were shown to be negative for any other relevant alterations,
with the exception of one case mutated in MEN1 and one carrying
CTNND2 inactivation. On the other side, the two quadruple WT cases
negative for FGF4 expression showed other relevant alterations: MAX
inactivation and a NF1 germline variant in one case and a FGFR1 p.
N546K activating mutation in the other.10
In previous works, quadrupleWT GIST have been shown to carry a
homogeneous signature profile,9,10 however, no recurrent genetic
alteration has been detected so far.13 Interestingly, among the alter-
ations identified, three different events affecting FGFR1 were
detected: FGFR1 p.N546K mutation10,11 and FGFR1-HOOK3 and
FGFR1-TACC1 fusion genes.11 These events are predicted to constitu-
tively activate FGFR1 and the downstream signaling pathways.
A mechanism of an autocrine FGF2/FGFR1 activation loop controlling
AKT signaling has been identified in many cancer histotypes, including
non small cell lung cancer and malignant pleural mesothelioma, in
which it may be predictive of drug response.29,30 Intriguingly, FGF4 is
reported to be a ligand of all four FGF receptors, including FGFR1,
which we have demonstrated to be highly expressed in GIST including
quadruple WT cases. It could be hypothesized that in these
FGF4-positive GIST, an autocrine loop between FGF4 and FGFR1 is
present, supporting tumor growth. Indeed, we demonstrated that sig-
naling through AKT is active in quadruple WT GIST, suggesting that, in
the absence of KIT phosphorylation, activation of FGFR1 through the
autocrine loop could stimulate downstream signaling. Interestingly,
the case harboring FGFR1 p.N546K mutation did not show expression
of FGF4, suggesting that only one alteration in the same pathway is
necessary and sufficient to activate downstream signaling. Additional
studies further investigating the role of FGF4 overexpression in tumor
growth and in FGFR signaling activation will be necessary to confirm
these hypotheses.
Altogether, these findings support a potential involvement in disease
onset of the FGFR pathway deregulation shared by all quadruple
WT GIST suggesting a possible role for FGRF inhibitors. Evaluation of
nonselective FGFR inhibitors (eg, regorafenib, sorafenib, ponatinib,
pazopanib, dovitinib) was well known, however no information on the
activity of these treatments are available specifically in KIT/PDGFRA
WT GIST.31 Therefore, selective FGFR inhibitors (eg, AZD4547,
BGJ398) could be considered for the treatment of this subgroup of
GIST. Recently, a cross-talk between KIT and FGFR playing an impor-
tant role in imatinib resistance was reported and a clinical trial with
BGJ398 in combination with imatinib was conducted in advanced
GIST.32,33 In our series, no patient had received treatment with FGFR
inhibitors.
Due to the small number of cases and the clinical heterogeneity, we
cannot postulate any definitive consideration regarding the prognostic or
predictive significance or clinical association of FGF3/FGF4 duplication
from our series. In fact, in localized cases risk of recurrence ranged from
very low to high, while the two metastatic cases did not receive
regorafenib. There was no gender or age predominance in patients. The
only interesting clinical data were that all quadruple WT cases developed
GIST in the small bowel and did not present lymph nodes metastases, as
these occur mostly in SDH-deficient GIST.
In conclusion, for the first time a recurrent event shared by qua-
druple WT GIST is reported in this study, even if these findings should
be tested and confirmed in larger series. Gain of FGF4, together with
FGFR1 mutations, represents the most frequent molecular alteration
identified in this subgroup so far, suggesting that these specific driver
events could aid the diagnostic process of KIT/PDGFRA/SDH/RAS-P
WT GIST, that are currently still diagnosed only by exclusion, and,
most important, that FGFR pathway activation could provide a ratio-
nale for targeted therapeutic approaches.
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